Peripheral benzodiazepine receptor (PBR) is upregulated in activated glial cells and is therefore a useful biomarker for inflammation in the brain and neurodegenerative disorders. We developed a new PET radioligand, \(^{11}\text{C}-\text{N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-pheryl-7,8-dihydro-9H-purin-9-yl)}\text{acetamide (AC-5216), that allows the imaging and quantification of PBRs in monkey and mouse brains. The aim of this study was to evaluate a quantification method of \(^{11}\text{C}-\text{AC-5216}^\text{binding in the human brain. Methods: A 90-min dynamic PET scan was obtained for each of 12 healthy men after an intravenous injection of \(^{11}\text{C-AC-5216}}\). Regions of interest were drawn on several brain regions. Binding potential, compared with nondisplaceable uptake (BP\(_{\text{ND}}\)), was calculated by a nonlinear least-squares fitting (NLS) method with the 2-tissue-compartment model, and total volume (VT) was estimated by NLS and graphical analysis methods. Results: BP\(_{\text{ND}}\) was highest in the thalamus (4.6 ± 1.0) and lowest in the striatum (3.5 ± 0.7). VT obtained by NLS or graphical analysis showed regional distribution similar to BP\(_{\text{ND}}\). However, there was no correlation between BP\(_{\text{ND}}\) and VT because of the interindividual variation of \(K_i/k_2\). BP\(_{\text{ND}}\) obtained with data from a scan time of 60 min was in good agreement with that from a scan time of 90 min (\(r = 0.87\). Conclusion: Regional distribution of \(^{11}\text{C}-\text{AC-5216}^\text{was in good agreement with previous PET studies of PBRs in the human brain. BP\(_{\text{ND}}\) is more appropriate for estimating \(^{11}\text{C}-\text{AC-5216}^\text{binding than is VT because of the interindividual variation of \(K_i/k_2\). \(^{11}\text{C}-\text{AC-5216}^\text{is a promising PET ligand for quantifying PBR in the human brain. Key Words: \(^{11}\text{C}-\text{AC-5216}; peripheral benzodiazepine receptor; microglia; human brain; positron emission tomography J Nucl Med 2009; 50:1095–1101 DOI: 10.2967/jnumed.109.062554

Received Jan. 26, 2009; revision accepted Mar. 12, 2009. For correspondence or reprints contact: Hiroshi Ito, Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan; E-mail: hito@nirs.go.jp COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
(inhibition constant, 0.297 nM) was higher than PK11195 (0.602 nM) (29) and lower than DAA1106 (36–108 pM) (30). AC-5216 exhibited negligible affinity for CBR and other receptors, monoamine transporters, and ion channels. The synthesis of $^{11}$C-labeled AC-5216 ($^{11}$C-AC-5216) and its high accumulation in the mouse brain have been reported (31). A PET study in monkeys demonstrated high uptake of $^{11}$C-AC-5216 in the brain, and the binding was inhibited by unlabeled AC-5216 and PK11195 (31). $^{11}$C-AC-5216 can be used for the clinical investigation of PBR expression and therefore also microglia activation in neurologic diseases, but the quantification method of $^{11}$C-AC-5216 binding in the living human brain has not yet been established. In the present study, PET measurements with $^{11}$C-AC-5216 were performed on healthy human subjects. We evaluated kinetic analysis methods for the quantification of $^{11}$C-AC-5216 binding in the human brain.

**MATERIALS AND METHODS**

**Subjects**

Twelve male healthy volunteers (age range, 20–33 y; mean age ± SD, 24.6 ± 4.5 y) participated in this study. All volunteers were free of any somatic, neurologic, or psychiatric disorders, and they had no history of current or previous drug abuse. This study was approved by the ethics and radiation safety committees of the National Institute of Radiologic Sciences. Written informed consent was obtained from each subject.

**Radioligand Preparation**

$^{11}$C-AC-5216 was synthesized as described previously (31). In brief, AC-5216 and its desmethyl precursor were synthesized starting from commercially available compounds. $^{11}$C-AC-5216 was radiosynthesized through the reaction of the precursor with $^{11}$C-CH$_3$I in the presence of sodium hydride.

**PET**

An ECAT EXACT HR+ PET scanner system (CTI-Siemens) was used for all measurements. A head-fixation device was used to minimize head movement. A transmission scan for attenuation correction was obtained using a $^{68}$Ge/$^{68}$Ga source. Dynamic PET scans were obtained after a 1-min intravenous slow bolus injection of $^{11}$C-AC-5216 (354.6–385.1 MBq [372.8 ± 9.7 MBq]). The specific radioactivities were 93.7–224.2 GBq/µmol (148.2 ± 35.6 GBq/µmol) at the time of injection. Brain radioactivities were measured from 0 to 90 min (20 s × 9, 60 s × 5, 120 s × 4, 240 s × 11, and 300 s × 6). MR images of the brain were acquired with a 1.5-T MRI scanner (Gyroscan NT; Philips). T1-weighted images were obtained at 1-mm slices.

**Arterial Blood Sampling**

To obtain the arterial input function, arterial blood samples were taken manually 32 times (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, and 150 s and 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, and 90 min after the radiotracer injection) during the PET scan. Each blood sample was centrifuged to obtain plasma and blood cell fractions, and the concentrations of radioactivity in whole blood and plasma were measured. Plasma protein binding was not determined in this study.

The percentage of unchanged $^{11}$C-AC-5216 in plasma was determined by high-performance liquid chromatography (HPLC) in 10 blood samples (3, 10, 20, 30, 40, 50, 60, 70, 80, and 90 min after injection). Acetonitrile was added to each plasma sample, and the samples were then centrifuged. The supernatant was subjected to radio–high-performance liquid chromatography analysis (column, XBridge Prep C18 [Waters]; mobile phase, 50% acetonitrile). The plasma input function was defined as the radioactivity of plasma multiplied by the percentage of unchanged radioligand.

**Regions of Interest (ROIs)**

All MR images were coregistered to PET images using PMOD (version 2.8; PMOD Technologies). Eleven ROIs were drawn manually on the PET images with reference to coregistered MR images. ROIs were delineated for the cerebellum, dorsolateral prefrontal cortex, medial prefrontal cortex, parietal cortex, lateral temporal cortex, medial temporal cortex, occipital cortex, anterior cingulate cortex, posterior cingulate cortex, striatum, and thalamus.

**Kinetic Model of $^{11}$C-AC-5216**

To describe the kinetics of $^{11}$C-AC-5216 in the brain, the 2-tissue-compartment model with 4 rate constants ($K_1, K_2, K_3, and K_4$) was used (32). The 3 compartments were defined as follows: $C_P$, the radioactivity concentration of unchanged radioligand in plasma (arterial input function); $C_{ND}$, the radioactivity concentration of nondisplaceable radioligand in brain, including nonspecifically bound and free radioligand; and $C_S$, the radioactivity concentration of radioligand specifically bound to receptors. The rate constants $K_1$ and $K_2$ represent the influx and efflux rates for radioligand diffusion through the blood–brain barrier. The rate constants $K_3$ and $K_4$ represent the radioligand transfers between the compartments for nondisplaceable and specifically bound radioligand. This model can be described by the following equations:

$$dC_{ND}(t)/dt = K_1 C_P(t) - (k_2 + k_3) C_{ND}(t) + k_4 C_S(t)$$

Eq. 1

$$dC_S(t)/dt = k_3 C_{ND}(t) - k_4 C_S(t)$$

Eq. 2

$$C_P(t) = C_{ND}(t) + C_S(t).$$

Eq. 3

$C_P(t)$ is the total radioactivity concentration in a brain region measured by PET. In this analysis, blood volume ($V_b$) was fixed to be 0.05 mL/mL (26).

**Calculation of $^{11}$C-AC-5216 Binding**

In the nonlinear least-squares fitting (NLS) method, $^{11}$C-AC-5216 bindings were expressed as binding potentials relative to nondisplaceable binding (BP$_{ND}$). BP$_{ND}$ can be expressed as:

$$BP_{ND} = f_{ND} B_{max}/K_d = k_3/k_4.$$  

Eq. 4

$B_{max}$ is the receptor density, $1/K_d$ is the affinity, and $f_{ND}$ is the free fraction of ligand in the nondisplaceable tissue compartment. We also calculated the total distribution volume ($V_T$), which can be expressed as:

$$V_T = K_1/k_2(1 + k_3/k_4).$$

Eq. 5

In the graphical analysis (GA) method, GA yields $V_T$ from the arterial input function and the tissue time–activity curve (33). Parameters are estimated from the equation:

1096  THE JOURNAL OF NUCLEAR MEDICINE • Vol. 50 • No. 7 • July 2009

jnmo62554-pm  ■  6/8/09
$\frac{\int_{t^*}^{T} CT(t)\,dt}{CT(T)} = V\int_{t^*}^{T} CP(t)\,dt + b \quad \text{for } T > t^*$, \hspace{1cm} \text{Eq. 6}

where $V$ represents $V_T$ after equilibration time $t^*$. Because $b$ becomes constant only after equilibration time $t^*$, $V$ and $b$ are estimated as a slope and an intercept, respectively, using the points of $T > t^*$. The starting time for linear regression $t^*$ was set at 30 min.

In these methods, the PET scan data for 90 min and those for 60 min were used. For these analyses, PMOD was used.

**RESULTS**

Typical summed PET images (0–10, 10–30, 30–60, and 60–90 min) and T1-weighted MR images are shown in Figure 1. The distribution of radioactivity was widespread and fairly uniform in the gray matter of the cerebral cortices and cerebellum, striatum, and thalamus. Typical time–activity curves of measured brain regions are shown in Figure 2. After an intravenous injection of $^{11}$C-AC-5216, radioactivity peaked at about 2–3 min, followed by slow washout. The average percentage of unchanged $^{11}$C-AC-5216 in plasma was $99.8\% \pm 0.2\%$ at 3 min, $89.1\% \pm 4.5\%$ at 30 min, and $69.6\% \pm 12.0\%$ at 90 min (mean ± SD) (Fig. 3).

The $K_1$, $K_1/k_2$, $k_3$, $k_3/k_4$, and $V_T$ values estimated by NLS and $V_T$ estimated by GA are listed in Tables 1 and 2 for scan times of 90 and 60 min, showing the mean and coefficient of variation (COV) (SD/mean [%]) of all ROIs. Although the mean $V_T$ values estimated by GA were larger than those by NLS in all regions, good correlation was observed between them ($r = 0.93$, $P < 0.001$) (Fig. 4). However, no correlation was observed between $BP_{ND}$

![FIGURE 1. Typical summed PET images from 0 to 10, 10 to 30, 30 to 60, and 60 to 90 min of $^{11}$C-AC-5216 and T1-weighted MR images.](image1)

![FIGURE 2. Typical time–activity curves of $^{11}$C-AC-5216 in occipital cortex, posterior cingulate cortex, thalamus, and cerebellum.](image2)

![FIGURE 3. Average percentage of unchanged $^{11}$C-AC-5216 in plasma. Bars indicate SD.](image3)
estimated by NLS and \( V_T \) estimated by NLS or GA for all regions (\( V_T \) by NLS, \( r = 0.31 \); \( V_T \) by GA, \( r = 0.19 \)) (Figs. 5A and 5B). \( BPND \) values estimated by NLS with a scan time of 60 min were in good agreement with those with a scan time of 90 min (\( V_T \) by NLS, \( r = 0.87 \), \( P < 0.001 \) (Fig. 6). \( V_T \) values estimated by NLS or GA with a scan time of 60 min were in good agreement with those with a scan time of 90 min (\( V_T \) by NLS, \( r = 0.82 \), \( P < 0.001 \); \( V_T \) by GA, \( r = 0.92 \), \( P < 0.001 \)).

**DISCUSSION**

This study describes the first, to our knowledge, quantitative analysis of PET measurement with \(^{11}\text{C-AC-5216}\) for PBR binding in the living human brain. Intravenous injection of \(^{11}\text{C-AC-5216}\) showed radioactivity to peak at about 2–3 min, followed by slow washout, similar to the pattern of \(^{11}\text{C-DAA1106}\) in animal (31) and human studies (26). \( BPND \) was highest in the thalamus in this study, consistent with \(^{11}\text{C-PK11195}\) (18) and \(^{11}\text{C-DAA1106}\) (26) studies. \( BPND \) was relatively higher in the medial temporal cortex and cerebellum and lower in the striatum, which was also consistent with \(^{11}\text{C-DAA1106}\) (26). \( V_T \) obtained by NLS or GA showed regional distribution similar to \( BPND \) in this study, whereas \( V_T \) was highest in the cerebellum in the \(^{11}\text{C-DAA1106}\) study (26).

Although \( V_T \) showed regional distribution similar to \( BPND \), \( BPND \) did not correlate with \( V_T \) obtained by NLS or GA. The COVs of \( k_1/k_2 \) (mean, 27.5; range, 17.6–34.4) were larger than those of \( k_3/k_4 \) (mean, 22.8; range, 19.3–26.9), indicating that the interindividual variation of \( k_1/k_2 \) rather than \( k_3/k_4 \) may have been due to errors in plasma input functions, including interindividual variation of plasma protein binding of the radioligand, and that \( BPND \) with the NLS method was the most appropriate for the quantification of \(^{11}\text{C-DAA1106}\) binding (26).

### TABLE 1. Average Values of Parameters Estimated by Each Method with 90-Minute Scan Time (\( n = 12 \))

<table>
<thead>
<tr>
<th>Method</th>
<th>( K_1 )</th>
<th>( K_1/k_2 )</th>
<th>( k_3 )</th>
<th>( k_3/k_4 )</th>
<th>( V_T )</th>
<th>GA (( V_T ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLS</td>
<td>0.184 (24.4)</td>
<td>1.40 (28.7)</td>
<td>0.091 (32.8)</td>
<td>4.25 (26.7)</td>
<td>5.70 (25.5)</td>
<td>6.64 (22.9)</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.174 (29.8)</td>
<td>1.60 (22.6)</td>
<td>0.072 (25.7)</td>
<td>3.47 (19.4)</td>
<td>5.49 (25.1)</td>
<td>6.40 (22.5)</td>
</tr>
<tr>
<td>Dorsolateral frontal</td>
<td>0.171 (28.2)</td>
<td>1.46 (19.5)</td>
<td>0.079 (24.4)</td>
<td>3.61 (20.9)</td>
<td>5.21 (26.6)</td>
<td>6.14 (24.0)</td>
</tr>
<tr>
<td>Medial frontal</td>
<td>0.175 (27.6)</td>
<td>1.55 (19.3)</td>
<td>0.076 (23.2)</td>
<td>3.53 (20.5)</td>
<td>5.41 (25.2)</td>
<td>6.42 (22.4)</td>
</tr>
<tr>
<td>Parietal</td>
<td>0.170 (27.2)</td>
<td>1.50 (22.5)</td>
<td>0.079 (24.0)</td>
<td>3.75 (23.0)</td>
<td>5.49 (25.8)</td>
<td>6.45 (22.8)</td>
</tr>
<tr>
<td>Lateral temporal</td>
<td>0.146 (28.1)</td>
<td>1.33 (25.8)</td>
<td>0.077 (31.2)</td>
<td>4.40 (28.6)</td>
<td>5.72 (31.4)</td>
<td>6.08 (27.9)</td>
</tr>
<tr>
<td>Medial temporal</td>
<td>0.197 (23.6)</td>
<td>1.47 (24.7)</td>
<td>0.097 (22.5)</td>
<td>4.18 (19.3)</td>
<td>6.08 (30.0)</td>
<td>7.08 (25.4)</td>
</tr>
<tr>
<td>Occipital</td>
<td>0.172 (30.8)</td>
<td>1.38 (23.8)</td>
<td>0.075 (32.6)</td>
<td>4.11 (26.9)</td>
<td>5.58 (28.9)</td>
<td>6.22 (25.3)</td>
</tr>
<tr>
<td>Anterior cingulate</td>
<td>0.222 (23.9)</td>
<td>1.44 (34.4)</td>
<td>0.110 (30.3)</td>
<td>4.37 (24.6)</td>
<td>5.97 (28.0)</td>
<td>7.08 (25.9)</td>
</tr>
<tr>
<td>Posterior cingulate</td>
<td>0.159 (22.5)</td>
<td>1.43 (17.6)</td>
<td>0.074 (23.1)</td>
<td>3.46 (20.2)</td>
<td>4.94 (30.3)</td>
<td>5.66 (22.4)</td>
</tr>
<tr>
<td>Striatum</td>
<td>0.186 (29.6)</td>
<td>1.51 (24.2)</td>
<td>0.085 (34.9)</td>
<td>4.64 (20.5)</td>
<td>6.86 (26.0)</td>
<td>7.39 (24.7)</td>
</tr>
</tbody>
</table>

Values are mean, with COV in parentheses.

### TABLE 2. Average Values of Parameters Estimated by Each Method with 60-Minute Scan Time (\( n = 12 \))

<table>
<thead>
<tr>
<th>Method</th>
<th>( K_1 )</th>
<th>( K_1/k_2 )</th>
<th>( k_3 )</th>
<th>( k_3/k_4 )</th>
<th>( V_T )</th>
<th>GA (( V_T ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLS</td>
<td>0.183 (25.1)</td>
<td>1.38 (25.5)</td>
<td>0.097 (28.3)</td>
<td>3.89 (26.5)</td>
<td>5.22 (24.5)</td>
<td>6.06 (21.5)</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.172 (31.0)</td>
<td>1.63 (18.7)</td>
<td>0.071 (31.3)</td>
<td>3.35 (22.0)</td>
<td>5.37 (22.9)</td>
<td>6.04 (23.9)</td>
</tr>
<tr>
<td>Dorsolateral frontal</td>
<td>0.171 (28.8)</td>
<td>1.42 (18.1)</td>
<td>0.085 (28.1)</td>
<td>3.48 (21.5)</td>
<td>4.91 (25.1)</td>
<td>5.66 (23.3)</td>
</tr>
<tr>
<td>Medial frontal</td>
<td>0.175 (28.3)</td>
<td>1.53 (17.4)</td>
<td>0.079 (27.0)</td>
<td>3.46 (20.8)</td>
<td>5.25 (23.7)</td>
<td>6.10 (22.8)</td>
</tr>
<tr>
<td>Parietal</td>
<td>0.170 (28.1)</td>
<td>1.45 (19.8)</td>
<td>0.087 (28.3)</td>
<td>3.64 (23.8)</td>
<td>5.17 (23.7)</td>
<td>6.02 (22.3)</td>
</tr>
<tr>
<td>Lateral temporal</td>
<td>0.147 (29.0)</td>
<td>1.27 (25.3)</td>
<td>0.089 (36.8)</td>
<td>4.31 (27.5)</td>
<td>5.32 (29.9)</td>
<td>5.50 (26.9)</td>
</tr>
<tr>
<td>Occipital</td>
<td>0.198 (24.5)</td>
<td>1.41 (22.1)</td>
<td>0.107 (26.9)</td>
<td>4.06 (19.5)</td>
<td>5.67 (26.0)</td>
<td>6.68 (22.5)</td>
</tr>
<tr>
<td>Anterior cingulate</td>
<td>0.173 (32.0)</td>
<td>1.31 (22.9)</td>
<td>0.089 (42.7)</td>
<td>3.88 (26.6)</td>
<td>4.94 (23.7)</td>
<td>5.47 (22.7)</td>
</tr>
<tr>
<td>Posterior cingulate</td>
<td>0.225 (24.4)</td>
<td>1.43 (35.7)</td>
<td>0.139 (35.0)</td>
<td>4.35 (26.2)</td>
<td>5.38 (27.9)</td>
<td>6.36 (25.6)</td>
</tr>
<tr>
<td>Striatum</td>
<td>0.169 (23.2)</td>
<td>1.46 (18.2)</td>
<td>0.073 (19.4)</td>
<td>3.39 (19.1)</td>
<td>4.86 (25.5)</td>
<td>5.35 (22.2)</td>
</tr>
<tr>
<td>Thalamus</td>
<td>0.199 (30.5)</td>
<td>1.56 (23.9)</td>
<td>0.094 (40.8)</td>
<td>4.49 (22.0)</td>
<td>6.45 (28.0)</td>
<td>6.66 (25.5)</td>
</tr>
</tbody>
</table>

Values are mean, with COV in parentheses.
$K_1/k_2$ of $^{11}$C-AC-5216 were similar to those of $^{11}$C-DAA1106 (mean, 26.2; range, 22.0–30.4). Thus, we concluded that BPND is more appropriate for the quantification of $^{11}$C-AC-5216 binding than VT.

For clinical research, a short scan time is preferred. In the present study, the BPND values obtained by the NLS method with a scan time 60 min were in good agreement with those obtained with a scan time of 90 min ($r = 0.87, P < 0.001$). VT values estimated by NLS or GA with a scan time of 60 min were also in good agreement with those with a scan time of 90 min ($V_T$ by NLS, $r = 0.82, P < 0.001$; $V_T$ by GA, $r = 0.92, P < 0.001$). These results suggest that the scan time of 60 min would be valid for clinical studies.

$^{11}$C-AC-5216 is suitable for the in vivo quantification of PBR in human subjects, because our recent investigation of animal models has indicated roles of PBR-positive microglia and astrocytes in neurodegenerative processes (34,35). Indeed, the monitoring of PBR levels in living brains could provide mechanistic insights into Alzheimer disease and allied dementias, in consideration of the intimate links between amyloid plaques and reactive astrocytes expressing PBR in mice transgenic for amyloid precursor protein (APP) (35), and between the accumulation of phosphorylated tau proteins and PBR-positive microglia in transgenic mice overexpressing a frontotemporal dementia with parkinsonism-17 (FTDP-17) mutant tau (35,36). Although we have also revealed elevated levels of PBR in multiple regions of Alzheimer disease brains as measured with $^{11}$C-DAA1106 (28), detection of earlier changes in this component is required for elucidating how the gliotic reactions extensively spread in the course of the aging–disease continuum. In this consideration, our PET assays of PBR in APP and tau transgenics have shown the superiority of $^{11}$C-AC-5216 to other existing radioligands in sensitively capturing gliial responses to the hallmark pathologies in these animals (Jun Maeda et al., unpublished data), supporting the potential utility of $^{11}$C-AC-5216 for the pursuit of neurodegenerative pathologies in humans from an incipient stage.

Accuracy in the measurements of PBR by means of PET would also be critical for gaining statistical power in assessing the neuroinflammatory status after therapies of neurologic conditions. As demonstrated by our PET scans of APP transgenic mice receiving an antibody against amyloid β peptide using $^{18}$F-FEDA1106 and an amyloid-binding radiotracer, $^{11}$C-Pittsburgh compound-B (37), PBR and amyloid ligands may conjunctively allow clarification of relationships between amyloid removal and glial activations yielded by the amyloid β immunization. In addition, the amounts of initially existing amyloid were found to positively correlate with the neuroinflammation provoked by the immunization (37), and this observation highlights the need for rigorous regulation of the glial response within an appropriate range to avoid treatment-induced microglial overactivations, which may accelerate

REFERENCES


